A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma von BEATTY, Gregory L, TORIGIAN, Drew A, O'DWYER, Peter J, GABRIELA CHIOREAN, E, SABOURY, Babak, BROTHERS, Alex, ALAVI, Abass, TROXEL, Andrea B, WEIJING SUN, TEITELBAUM, Ursina R, VONDERHEIDE, Robert H

Volltext

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine von Von Hoff, Daniel D, Ervin, Thomas, Arena, Francis P, Chiorean, E. Gabriela, Infante, Jeffrey, Moore, Malcolm, Seay, Thomas, Tjulandin, Sergei A, Ma, Wen Wee, Saleh, Mansoor N, Harris, Marion, Reni, Michele, Dowden, Scot, Laheru, Daniel, Bahary, Nathan, Ramanathan, Ramesh K, Tabernero, Josep, Hidalgo, Manuel, Goldstein, David, Van Cutsem, Eric, Wei, Xinyu, Iglesias, Jose, Renschler, Markus F

Volltext

Colorectal Cancer Detection Using Targeted Serum Metabolic Profiling von Zhu, Jiangjiang, Djukovic, Danijel, Deng, Lingli, Gu, Haiwei, Himmati, Farhan, Chiorean, E. Gabriela, Raftery, Daniel

Volltext

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies von Chiorean, Elena Gabriela, Coveler, Andrew L

Volltext

The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer von Jia, Yanfei, Gu, Dongsheng, Wan, Jun, Yu, Beiqin, Zhang, Xiaoli, Chiorean, E. Gabriela, Wang, Yunshan, Xie, Jingwu

Volltext

Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline von Chiorean, E Gabriela, Nandakumar, Govind, Fadelu, Temidayo, Temin, Sarah, Alarcon-Rozas, Ashley Efrain, Bejarano, Suyapa, Croitoru, Adina-Emilia, Grover, Surbhi, Lohar, Pritesh V, Odhiambo, Andrew, Park, Se Hoon, Garcia, Erika Ruiz, Teh, Catherine, Rose, Azmina, Zaki, Bassem, Chamberlin, Mary D

Volltext

The role of the folate pathway in pancreatic cancer risk von Chittiboyina, Shirisha, Chen, Zhongxue, Chiorean, E Gabriela, Kamendulis, Lisa M, Hocevar, Barbara A

Volltext

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313 von Ramanathan, Ramesh K, McDonough, Shannon L, Philip, Philip A, Hingorani, Sunil R, Lacy, Jill, Kortmansky, Jeremy S, Thumar, Jaykumar, Chiorean, E Gabriela, Shields, Anthony F, Behl, Deepti, Mehan, Paul T, Gaur, Rakesh, Seery, Tara, Guthrie, Katherine A, Hochster, Howard S

Volltext

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients wit... von Chiorean, E.G., Hurwitz, H.I., Cohen, R.B., Schwartz, J.D., Dalal, R.P., Fox, F.E., Gao, L., Sweeney, C.J.

Volltext

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies von Mahadevan, D, Chiorean, E.G, Harris, W.B, Von Hoff, D.D, Stejskal-Barnett, A, Qi, W, Anthony, S.P, Younger, A.E, Rensvold, D.M, Cordova, F, Shelton, C.F, Becker, M.D, Garlich, J.R, Durden, D.L, Ramanathan, R.K

Volltext

Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study von Hardacre, Jeffrey M., Mulcahy, Mary, Small, William, Talamonti, Mark, Obel, Jennifer, Krishnamurthi, Smitha, Rocha-Lima, Caio S., Safran, Howard, Lenz, Heinz-Joseph, Chiorean, E. Gabriela

Volltext

Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer von Wainberg, Zev A, Hochster, Howard S, Kim, Edward J, George, Ben, Kaylan, Aparna, Chiorean, E Gabriela, Waterhouse, David M, Guiterrez, Martin, Parikh, Aparna, Jain, Rishi, Carrizosa, Daniel Ricardo, Soliman, Hatem H, Lila, Thomas, Reiss, David J, Pierce, Daniel W, Bhore, Rafia, Banerjee, Sibabrata, Lyons, Larry, Louis, Chrystal U, Ong, Teng Jin, O'Dwyer, Peter J

Volltext

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 von SPRATLIN, Jennifer L, COHEN, Roger B, MEROPOL, Neal J, LEWIS, Nancy L, CHIOREAN, E. Gabriela, FOX, Floyd, YOUSSOUFIAN, Hagop, ROWINSKY, Eric K, GAIL ECKHARDT, S, EADENS, Matthew, GORE, Lia, CAMIDGE, D. Ross, DIAB, Sami, LEONG, Stephen, O'BRYANT, Cindy, CHOW, Laura Q. M, SERKOVA, Natalie J

Volltext

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study von Bekaii-Saab, Tanios S, Prof, Ou, Fang-Shu, PhD, Ahn, Daniel H, DO, Boland, Patrick M, MD, Ciombor, Kristen K, MD, Heying, Erica N, BS, Dockter, Travis J, MS, Jacobs, Nisha L, MD, Pasche, Boris C, Prof, Cleary, James M, MD, Meyers, Jeffrey P, BS, Desnoyers, Rodwige J, MD, McCune, Jeannine S, Prof, Pedersen, Katrina, MD, Barzi, Afsaneh, MD, Chiorean, E Gabriela, Prof, Sloan, Jeffrey, Prof, Lacouture, Mario E, Prof, Lenz, Heinz-Josef, Prof, Grothey, Axel, MD

Volltext

A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma von Gbolahan, Olumide B., Porter, Ryan F., Salter, John T., Yiannoutsos, Constantin, Burns, Matthew, Chiorean, E. Gabriella, Loehrer, Patrick. J.

Volltext

The role of molecular testing in pancreatic cancer von Zhen, David B., Safyan, Rachael A., Konick, Eric Q., Nguyen, Ryan, Prichard, Colin C., Chiorean, E. Gabriela

Volltext

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer von Chiorean, E Gabriela, Von Hoff, Daniel D, Tabernero, Josep, El-Maraghi, Robert, Ma, Wen Wee, Reni, Michele, Harris, Marion, Whorf, Robert, Liu, Helen, Li, Jack Shiansong, Manax, Victoria, Romano, Alfredo, Lu, Brian, Goldstein, David

Volltext

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer von Byrne, Katelyn T, Betts, Courtney B, Mick, Rosemarie, Sivagnanam, Shamilene, Bajor, David L, Laheru, Daniel A, Chiorean, E Gabriela, O'Hara, Mark H, Liudahl, Shannon M, Newcomb, Craig, Alanio, Cécile, Ferreira, Ana P, Park, Byung S, Ohtani, Takuya, Huffman, Austin P, Väyrynen, Sara A, Dias Costa, Andressa, Kaiser, Judith C, Lacroix, Andreanne M, Redlinger, Colleen, Stern, Martin, Nowak, Jonathan A, Wherry, E John, Cheever, Martin A, Wolpin, Brian M, Furth, Emma E, Jaffee, Elizabeth M, Coussens, Lisa M, Vonderheide, Robert H

Volltext

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer von Borad, Mitesh J, Reddy, Shantan G, Bahary, Nathan, Uronis, Hope E, Sigal, Darren, Cohn, Allen L, Schelman, William R, Stephenson, Jr, Joe, Chiorean, E Gabriela, Rosen, Peter J, Ulrich, Brian, Dragovich, Tomislav, Del Prete, Salvatore A, Rarick, Mark, Eng, Clarence, Kroll, Stew, Ryan, David P

Volltext

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors von Raez, Luis E., Papadopoulos, Kyriakos, Ricart, Alejandro D., Chiorean, E. Gabriella, DiPaola, Robert S., Stein, Mark N., Rocha Lima, Caio M., Schlesselman, James J., Tolba, Khaled, Langmuir, Virginia K., Kroll, Stewart, Jung, Donald T., Kurtoglu, Metin, Rosenblatt, Joseph, Lampidis, Theodore J.

Volltext